Genscript Biotech Corp (1548) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Genscript Biotech Corp HK$22.17, price HK$44.86, upside -50.6%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Genscript Biotech Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range HK$8.23 – HK$44.86 · fair‑value band HK$13.25 – HK$41.60 · the HK$44.86 price screens above the HK$22.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow Genscript Biotech in your weekly email
Every Wednesday you see whether Genscript Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.
Show more
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease. In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank. It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wan Chai, Hong Kong.
Stock analysis
Genscript Biotech Corp (1548) currently trades at HK$44.86, while our model-based Fair Value estimate is HK$22.17, 50.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$23.52 per share, and 0 of the 13 models we run sit above the HK$44.86 price.
Bear case: the Earnings-Based group reads lowest at HK$7.99, and 13 of the 13 models stay below the price. Evidence for this calculation is medium.
Scenario range: HK$13.25 (bear) to HK$41.60 (bull), the price of HK$44.86 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Genscript Biotech Corp reported revenue of $960M in FY2025 versus $511M in FY2021, a compound +17.1%/yr. Reported net income was −$533M in FY2025.
Key figures
Market cap HK$98.0B (≈ $12.5B) · P/E ex one-offs 54.4 · Net margin −55.5% · Return on equity −15.3% · Return on assets (EBIT) −6.6% · Operating margin 12.3% · Revenue (TTM) $845M · Revenue growth (YoY) −22.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 323% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −51%, 1548 screens richer than that median.
Fair Value models
Bear HK$13.25Fair Value HK$22.17Bull HK$41.60
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+61.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.7%
Start year 2020 (pandemic). Over 10 years: +27.2% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−52.3% (2020) → 26.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+26.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +23.7% a year for the price and +9.3% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (91 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 638 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside−50.6% · Below median
Profitability
Return on assets1.5% · Above median
Net margin (TTM)−75.4% · Bottom 25%
Operating margin (TTM)12.3% · Above median
Growth and dividend
Revenue growth−22.1% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B3.16× · Pricier than median
P/S (TTM)14.79× · Priciest 25%
P/FCF51.7× · Priciest 25%
EV/EBITDA64.0× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Genscript Biotech Corp (1548) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of HK$22.17 versus a price of HK$44.86, about −51% upside (overvalued).
What is the fair value of 1548?
Our model-based fair value for Genscript Biotech Corp is HK$22.17 (as of Oct 1, 2026), built from audited fundamentals. The current price: HK$44.86.
What is the quality score of 1548?
Genscript Biotech Corp has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genscript Biotech Corp (1548)?
Our model-based price target is the fair value of HK$22.17 (as of Oct 1, 2026) from 13 valuation models. Cautious scenario HK$13.25, optimistic scenario HK$41.60. It is a calculation from audited fundamentals, not an analyst target.
What is the Genscript Biotech Corp stock forecast for 2026?
Our models put fair value at HK$22.17, about −51% upside versus a price of HK$44.86 (overvalued). Cautious scenario HK$13.25, optimistic scenario HK$41.60. The calculation is refreshed regularly with new filings.
What is the revenue of Genscript Biotech Corp (1548)?
Genscript Biotech Corp reported trailing-twelve-month revenue of about $845M (latest available figure, as of Oct 1, 2026).
What growth is priced into Genscript Biotech Corp (1548)?
For today's price to be fair in a discounted-cash-flow model, Genscript Biotech Corp would have to grow free cash flow by +26.6 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +19.7 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of 1548 use?
Our models discount Genscript Biotech Corp at 9.7 %: a base by market capitalisation (large), damped by beta 0.98, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Genscript Biotech Corp that is +26.6 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Genscript Biotech Corp (1548) delivered so far?
Over the past 5 years revenue at Genscript Biotech Corp grew +19.7 % a year. The price currently implies +26.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Genscript Biotech Corp (1548) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Genscript Biotech Corp (+26.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Genscript Biotech Corp (1548)?
The free-cash-flow yield on the price is 1.93 %: that much free cash flow Genscript Biotech Corp produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Genscript Biotech Corp (1548)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genscript Biotech Corp it is HK$22.17 per share (as of Oct 1, 2026), against a price of HK$44.86. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Genscript Biotech Corp stock overvalued or undervalued in 2026?
As of Oct 1, 2026, 1548 trades above its calculated fair value: price HK$44.86, fair value HK$22.17, a gap of about −51% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1548?
No. The price is what the market pays today (HK$44.86); the fair value is what the company's own numbers justify (HK$22.17). For Genscript Biotech Corp the two are HK$22.69 per share apart. That gap is exactly why we show both numbers side by side.
How much is Genscript Biotech Corp worth?
The market values Genscript Biotech Corp at about HK$98.0B (market capitalisation, as of Oct 1, 2026). Per share that is HK$44.86; our models calculate a fair value of HK$22.17 per share.
What do the bullish and bearish scenarios say about 1548?
Our models span a range for Genscript Biotech Corp: cautious scenario HK$13.25, base HK$22.17, optimistic HK$41.60 per share (as of Oct 1, 2026, price HK$44.86). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genscript Biotech Corp (1548)?
Balance-sheet figures for Genscript Biotech Corp (as of Oct 1, 2026): return on equity −15.3%. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 1548 from its 52-week high?
Genscript Biotech Corp trades at HK$44.86, at its 52-week high of HK$44.86 and 323% above the low of HK$10.60 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$22.17 is for.
Which stocks are comparable to Genscript Biotech Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genscript Biotech Corp stock attractive at the current price?
The data as of Oct 1, 2026: price HK$44.86, calculated fair value HK$22.17 (−51%), Quality Score 55/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1548 calculated?
We run Genscript Biotech Corp through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$22.17, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Genscript Biotech Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genscript Biotech Corp (1548)?
The closing price on Sep 30, 2026 was HK$44.86. Our model-based fair value is HK$22.17, about −51% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genscript Biotech Corp right now?
The price sits above even our optimistic bull case (HK$41.60). The favourable scenario is already priced in. The model range is unusually wide (HK$13.25 to HK$41.60). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Genscript Biotech Corp
How large is the market capitalisation of Genscript Biotech Corp (1548)?
The market capitalisation of Genscript Biotech Corp is HK$98.0B (≈ $12.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Genscript Biotech Corp (1548) excluding one-off items?
Excluding one-off items, the price-to-earnings ratio of Genscript Biotech Corp is 54.4 (fiscal year 2025, the reported result was a loss).
What is the net margin of Genscript Biotech Corp (1548)?
The net margin of Genscript Biotech Corp is −55.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genscript Biotech Corp (1548)?
The return on equity (ROE) of Genscript Biotech Corp is −15.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genscript Biotech Corp (1548)?
On an EBIT basis the return on assets of Genscript Biotech Corp is −6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genscript Biotech Corp (1548)?
The operating margin of Genscript Biotech Corp is 12.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genscript Biotech Corp (1548)?
Revenue at Genscript Biotech Corp is growing −22.1% versus a year earlier (3y avg +15.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Genscript Biotech Corp (1548) carry?
The net debt of Genscript Biotech Corp is $116M (fiscal year 2025, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Genscript Biotech Corp in the live analysis
One click puts Genscript Biotech Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
